EVE Raises $1.1M as Dyspro™ Sees First Prescriptions and Libbo™ Nears Launch

Regulatory and Commercial Milestones

EVE Health Group (ASX – EVE) has marked a pivotal quarter as it transitions from development to commercial operations for its flagship products Dyspro™ and Libbo™. Both products recently cleared key regulatory hurdles under Australia’s Therapeutic Goods Administration (TGA), enabling prescription access through the Special Access Scheme and Authorised Prescriber pathways. This regulatory green light accelerated the commercial manufacture and distribution of Dyspro™, a cannabinoid-based gummy targeting dysmenorrhoea and endometriosis, with first patient prescriptions recorded shortly after the quarter ended.

Meanwhile, Libbo™, an oral dissolving film designed for erectile dysfunction, advanced through regulatory clearance and secured its first commercial purchase order in August 2025. Manufacturing is underway with a GMP-certified partner, aiming for product availability by December 2025. Libbo™ offers a discreet and fast-acting alternative in a global market valued at over US$5 billion annually, positioning EVE to tap into a significant unmet need in men’s health.

Supporting Commercial Launch and Education

To bolster Dyspro™’s market entry, EVE launched Reclaim My Cycle, an online hub dedicated to women’s health education and prescriber resources. This platform provides accessible information for patients managing dysmenorrhoea and endometriosis, alongside clinical guides and prescribing support for healthcare professionals. The initiative reflects EVE’s commitment to not only delivering innovative treatments but also fostering awareness and informed dialogue around these prevalent women’s health conditions.

Complementing these efforts, EVE established a Scientific Advisory Board to provide independent oversight and reinforce the evidence-based foundation of its pipeline. The inaugural appointment of Dr Fiona Cousins, a senior research scientist at the Hudson Institute of Medical Research, signals the company’s dedication to scientific rigor as it scales its commercial operations.

Financial Position and Outlook

Financially, EVE closed the quarter with $0.4 million in cash and raised an additional $1.1 million in a placement to sophisticated investors, exceeding its $1 million target. These funds are earmarked to accelerate the commercial rollout of Dyspro™ and Libbo™, support prescriber engagement, and advance regulatory registrations, including TGA Export-Only status and full ARTG submission. Operating costs remained stable, with customer receipts slightly down to $0.3 million.

Looking ahead, EVE plans to complete Libbo™’s commercial manufacture and launch a dedicated men’s health platform to support its market entry. The company also aims to expand prescriber education programs, appoint further Scientific Advisory Board members, and continue research and development to build a robust pipeline of next-generation products.

CEO Damian Wood emphasised the strategic shift – "This quarter represents a major step forward for EVE as we move from development into commercial operations. With Dyspro now reaching patients and Libbo in final manufacture, we are executing a clear strategy focused on bringing practical, evidence-based treatments to areas of real unmet need in women’s and men’s health."